메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background/Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistanthepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescuetherapy in decompensated patients infected with lamivudine-resistant HBV. Methods: In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at adosage of 10 mg/day for a median of 33 months in this multicenter cohort study. Results: Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2points, and the overall end-stage liver disease score decreased from 16±5 to 14±10 (mean ± SD, P<0.001) during thefollow-up period. With ADV treatment, 67 patients (56.3%) had undetectable serum HBV DNA (detection limit, 0.5 pg/mL). Virologic breakthrough occurred in 38 patients (36.1%) and 9 patients had a suboptimal ADV response. Theoverall survival rate was 89.9% (107/119), and a suboptimal response to ADV treatment was associated with both noimprovement in Child-Pugh score (≥2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012). Conclusions: Three years of ADV treatment was effective and safe in decompensated patients with lamivudine-resistant HBV.

목차

등록된 정보가 없습니다.

참고문헌 (23)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0